One of the earliest major projects of Associated Pharmacologists & Toxicologists (APT) was petitioning the US Food & Drug Administration (FDA) to reevaluate the safety of aluminum salts as components of over-the-counter (OTC) products. The APT petition to the FDA was submitted in 1981. At that time antacid products, such as Rolaids, were primarily aluminum salts. Detailed concerns about the potential safety risks with loading consumers, especially elderly consumers, with aluminum were described in detail in a 1985 paper (Lione, 1985). The origins of the concern with the potential toxicity of aluminum had come from the identification of dementias (and blood pathologies) that had developed in dialysis patients who had been dialyzed with tap water that had residual aluminum in it (Alfrey, 1980). The source of that aluminum was the residual water content from the use of aluminum salts in the treatment of tap water. As we get older, it is not uncommon for renal function to declin